An interventional study of Laser Lithotripsy with Moses Technology and Laser Lithotripsy with Vapor Tunnel in Lithiasis, Urinary, Stone, Urinary and Lithotripsy, Laser, sponsored by National and Kapodistrian University of Athens. Not yet recruiting at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by National and Kapodistrian University of Athens · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study is to compare two different laser settings used to break up kidney and ureter stones during surgery. The study will include adults with kidney or ureter stones who are scheduled to undergo a procedure in which an endoscope is passed through the urinary tract and a laser is used to break the stones into smaller pieces.
The main question is whether one laser setting can break up stones using less energy than the other, while maintaining similar treatment effectiveness and safety.
A total of 110 participants will be randomly assigned to one of two groups:
Both methods use a laser to break stones into smaller pieces. The study will compare the amount of laser energy used in relation to the size of the stone. Researchers will also assess the duration of the procedure, how completely the stones are cleared, the movement of stones during surgery, and any complications.
The findings may help urologists understand which laser setting is more efficient and whether it offers advantages during the treatment of kidney and ureter stones.
95 studies on the registry are indexed under Urinary Calculi; 19 are open to participants now.
This study's planned enrollment of 110 is close to the median of 120 across 61 interventional studies indexed under Urinary Calculi.
Browse Urinary Calculi studies →National and Kapodistrian University of Athens is the lead sponsor of 177 studies on the registry; 55 are open to participants now.
Compared within Urinary Calculi, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urolithiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Laser Lithotripsy with Moses Technology
Procedure: Laser Lithotripsy with Vapor Tunnel
Laser lithotripsy using Moses Technology pulse modulation by Lumenis Pulse 120H Ho:YAG laser system, that produces a two-part laser pulse. The first low-energy part produces a vapor cavity through which the second high-energy part is transmitted to the stone without energy loss, increasing laser efficacy.
Also known as: Ho:YAG Laser Lithotripsy
Laser lithotripsy using Vapor Tunnel pulse modulation by Quanta Cyber Ho Ho:YAG laser system, which creates one low-power long-length laser pulse that prevents stone retropulsion.
Also known as: Ho:YAG Laser Lithotripsy
Laser efficacy
Total energy delivered by the Ho:YAG laser during stone lithotripsy, divided by the preoperative stone volume measured on computed tomography (CT). The result will be expressed in joules per cubic millimeter (J/mm³).
Time frame: During ureteroscopic procedure
Laser-on time
The cumulative duration of laser activation during stone lithotripsy, measured in minutes and recorded by the laser system.
Time frame: During ureteroscopic procedure
Operative time
The total duration of the ureteroscopic procedure, measured in minutes from the beginning to the completion of the surgical procedure.
Time frame: During ureteroscopic procedure
Total energy
The cumulative energy delivered by the Ho:YAG laser during stone lithotripsy, measured in joules (J) and recorded by the laser system.
Time frame: During ureteroscopic procedure
Lithotripsy rate
Lithotripsy rate calculated as the preoperative stone volume, measured on CT in cubic millimeters, divided by the total laser activation time in seconds. Results will be expressed in mm³/s.
Time frame: During ureteroscopic procedure
Stone-free rate
The proportion of patients with no residual stone fragments larger than 3 mm on postoperative computed tomography (CT).
Time frame: One month after ureteral stent removal (ureteral stent removal typically removed 7-10 days after discharge)
Intraoperative complications
The proportion of patients experiencing one or more complications during the ureteroscopic procedure, including their type and nature.
Time frame: During ureteroscopic procedure
Postoperative complications
The proportion of patients experiencing postoperative complications, including their type and severity, classified according to the Clavien-Dindo classification system.
Time frame: Within 30 days after the ureteroscopic procedure
Length of hospital stay
The duration of hospitalization, calculated as the number of days from hospital admission to hospital discharge.
Time frame: From hospital admission until discharge
Stone retropulsion
Surgeon-assessed stone retropulsion during laser lithotripsy, evaluated according to the distance of stone displacement, frequency of retropulsion events, and impact of retropulsion on the completion of stone fragmentation.
Time frame: During ureteroscopic procedure
Plan to share: No
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 32 interventional studies with no phase under Urinary Calculi, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 79. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National and Kapodistrian University of Athens →